Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

Summary

Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of nasal glucagon (AMG504-1) in treating episodes of hypoglycemia. The population will be enriched to include participants who suffer from impaired hypoglycemia awareness.

Timeline

Start

2014-05

Primary completion

2015-08

Completion

2015-08

Drugs

Indications